Report : North America Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy, and Research), and End-User (Hospitals and Clinics, Research and Academic Institutes, and Diagnostic Centers)
CTC Detection and Enrichment Method Segment has the Largest Share of Technology in the North America Circulating Tumor Cell (CTC) Diagnostics Market during 2021–2028
According to our latest study on “North America Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Technology, Application, and End User,” the market is projected to reach US$ 1,664.0 million by 2028 from US$ 861.6 million in 2021; it is expected to grow at a CAGR of 9.9% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing prevalence of cancer across the region along with rising demand for minimally invasive diagnostic procedures. However, dearth of skilled professionals performing diagnostic procedures is expected to restrict the market growth during the forecast period.
The impact of the COVID-19 pandemic on people living with cancer, cancer surveillance capacities, and the whole American health system is the topic of this year's special segment. Reduced resources and availability to care as a result of the pandemic are expected to make cancer detection and treatment more difficult, resulting in lower incidence, higher mortality, and lower survival in the future. Because of a compromised immune system caused by the cancer and/or its treatment, people with active cancer are more susceptible to infectious pathogens (e.g., surgery and chemotherapy). This has raised fears that COVID-19 problems and mortality may be more common in cancer patients. Male sex, older age (60 years), a history of smoking, obesity, hypertension, cardiovascular disease, and diabetes have all been consistently related to an elevated risk of severe disease and/or death in cancer patients. Findings relating to prognosis for cancer-associated variables have proven conflicting.
Based on technology, the circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection and CTC analysis. In 2021, the CTC detection and enrichment segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 10.2% in the forecast period.
Thermo Fisher Scientific, Stemcell Technologies, Inc, QIAGEN, Precision Medicine Group, LLC, Advanced Cell Diagnostics (Bio-Techne Corporation), Epic Lifesciences, Screencell, Ikonisys, Inc, IV Diagnostics, Fluxion Biosciences are among the leading companies in the North America circulating tumor cell (CTC) diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for circulating tumor cell (CTC) diagnostics market is segmented into technology, application, and end user. Based on technology, the North America circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection and CTC analysis. Based on application, the circulating tumor cell (CTC) diagnostics market is segmented into clinical/liquid biopsy, and research. Based on end user, the circulating tumor cell (CTC) diagnostics market is segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Geographically, the circulating tumor cell (CTC) diagnostics market is segmented into North America (US, Canada, Mexico).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com